

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Ezetimibe / Atorvastatin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2      H373: May cause damage to organs through prolonged or repeated exposure.  
Long-term (chronic) aquatic hazard, Category 2      H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H373      May cause damage to organs through prolonged

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

H411      or repeated exposure.  
Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

P260      Do not breathe dust.  
P273      Avoid release to the environment.

**Response:**

P314      Get medical advice/ attention if you feel unwell.  
P391      Collect spillage.

**Hazardous components which must be listed on the label:**

Atorvastatin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|---------------|---|---|--------------------------|
| Atorvastatin  | 134523-03-8   | STOT RE 2; H373<br>(Liver, muscle)<br>Aquatic Chronic 2;<br>H411            | >= 10 - < 20             |
| Ezetimibe     | 163222-33-1   | Aquatic Chronic 1;<br>H410<br><br>M-Factor (Chronic<br>aquatic toxicity): 1 | >= 2.5 - < 10            |

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
- 

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.   |
| Local/Total ventilation | : | Use only with adequate ventilation.  |
| Advice on safe handling | : | Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.   |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |   |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents                           |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|
- 

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

dusts non-specific      4 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)  
Basis: IE OEL

10 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)  
Basis: IE OEL

| Components         | CAS-No.     | Value type (Form of exposure) | Control parameters             | Basis    |
|--------------------|-------------|-------------------------------|--------------------------------|----------|
| Cellulose          | 9004-34-6   | OELV - 8 hrs (TWA)            | 10 mg/m <sup>3</sup>           | IE OEL   |
| Atorvastatin       | 134523-03-8 | TWA                           | 0.05 mg/m <sup>3</sup> (OEB 3) | Internal |
|                    |             | Wipe limit                    | 0.5 mg/100 cm <sup>2</sup>     | Internal |
| Ezetimibe          | 163222-33-1 | TWA                           | 25 µg/m <sup>3</sup> (OEB 3)   | Internal |
|                    |             | Wipe limit                    | 250 µg/100 cm <sup>2</sup>     | Internal |
| Magnesium stearate | 557-04-0    | OELV - 8 hrs (TWA)            | 10 mg/m <sup>3</sup>           | IE OEL   |

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

|             |                         |
|-------------|-------------------------|
| Filter type | : Particulates type (P) |
|-------------|-------------------------|

sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to I.S. EN 143

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

|  |   |
|--|---|
| Physical state                                   | : powder  |
| Colour   | : off-white   |
| Odour  | : No data available   |
| Odour Threshold                                  | : No data available   |
| Melting point/freezing point                     | : No data available   |
| Initial boiling point and boiling range          | : No data available   |
| Flammability (solid, gas)                        | : May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : No data available   |
| Upper explosion limit / Upper flammability limit | : No data available   |
| Lower explosion limit / Lower flammability limit | : No data available   |
| Flash point                                      | : Not applicable  |
| Auto-ignition temperature                        | : No data available   |
| Decomposition temperature                        | : No data available   |
| pH   | : No data available   |
| Viscosity  |   |
| Viscosity, kinematic                             | : No data available   |
| Solubility(ies)                                  |   |
| Water solubility                                 | : 0.01 g/l  |
| Partition coefficient: n-octanol/water           | : No data available   |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

|                          |   |                   |
|--------------------------|---|-------------------|
| Vapour pressure          | : | No data available |
| Relative density         | : | No data available |
| Density                  | : | No data available |
| Relative vapour density  | : | No data available |
| Particle characteristics | : |                   |
| Particle size            | : | No data available |

### 9.2 Other information

|                      |   |  |
|----------------------|---|--|
| Explosives           | : | Not explosive  |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Evaporation rate     | : | No data available  |
| Molecular weight     | : | No data available  |

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

|                     |   |  |
|---------------------|---|--|
| Hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means.<br>Can react with strong oxidizing agents. |
|---------------------|---|--|

### 10.4 Conditions to avoid

|                     |   |   |
|---------------------|---|---|
| Conditions to avoid | : | Heat, flames and sparks.<br>Avoid dust formation. |
|---------------------|---|---|

### 10.5 Incompatible materials

|                    |   |                  |
|--------------------|---|------------------|
| Materials to avoid | : | Oxidizing agents |
|--------------------|---|------------------|

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

|  |   |   |
|--|---|---|
| Information on likely routes of exposure | : | Inhalation<br>Skin contact<br>Ingestion |
|--|---|---|



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

---

Eye contact

### Acute toxicity

Not classified based on available information.

### Components:

#### Atorvastatin:

Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg  
LD50 (Mouse, male and female): > 5,000 mg/kg

#### Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg  
LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): > 1,000 - < 2,000 mg/kg  
Application Route: Intraperitoneal

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Atorvastatin:

Species : Rabbit  
Result : No skin irritation

#### Ezetimibe:

Species : Rabbit  
Result : No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Atorvastatin:

Species : Rabbit  
Method : Draize Test  
Result : No eye irritation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### Ezetimibe:

Species : Rabbit  
Result : No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

### Components:

#### Atorvastatin:

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

#### Ezetimibe:

Test Type : Maximisation Test  
Species : Guinea pig  
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Atorvastatin:

Genotoxicity in vitro : Test Type: reverse mutation assay  
Test system: Salmonella typhimurium  
Result: negative

Test Type: reverse mutation assay  
Test system: Escherichia coli  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster lung cells  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Metabolic activation: with and without metabolic activation  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Atorvastatin:

Species : Mouse, male and female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
LOAEL : 400 mg/kg body weight  
Result : negative  
Target Organs : Liver

Species : Rat, female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
LOAEL : 100 mg/kg body weight  
Target Organs : Musculo-skeletal system

#### Ezetimibe:

Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

---

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Atorvastatin:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Fertility: NOAEL: 225 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Fertility: NOAEL: 175 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Species: Rat, female  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: No teratogenic effects, Embryo-foetal toxicity  
Remarks: Maternal toxicity observed.

Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 100 mg/kg body weight  
Result: No embryo-foetal toxicity

#### Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1,000 mg/kg body weight  
Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

---

### Components:

#### **Atorvastatin:**

Exposure routes : Ingestion  
Target Organs : Liver, muscle  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

#### Components:

#### **Atorvastatin:**

Species : Rat, male and female  
LOAEL : 70 mg/kg  
Application Route : oral (gavage)  
Exposure time : 52 Weeks  
Target Organs : Liver

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : oral (gavage)  
Exposure time : 104 Weeks  
Target Organs : Liver

#### **Ezetimibe:**

Species : Dog  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 1,500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Remarks : No significant adverse effects were reported

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Ezetimibe:

Not applicable

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

#### Atorvastatin:

Ingestion : Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

#### Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### Atorvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 200 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

---

|  |   |   |
|--|---|---|
|  |   | mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201  |
| Toxicity to microorganisms   | : | EC50 : > 1,000 mg/l<br>Exposure time: 3 h<br>Test Type: Respiration inhibition  |
| Toxicity to fish (Chronic toxicity)                                    | : | NOEC: 0.49 mg/l<br>Exposure time: 33 d<br>Species: Pimephales promelas (fathead minnow)<br>Method: OECD Test Guideline 210  |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC: 0.2 mg/l<br>Exposure time: 21 d<br>Species: Daphnia magna (Water flea)<br>Method: OECD Test Guideline 211   |
| <b>Ezetimibe:</b>  |   |   |
| Toxicity to fish   | : | LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 203<br>Remarks: No toxicity at the limit of solubility          |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): > 4 mg/l<br>Exposure time: 48 h<br>Method: OECD Test Guideline 202<br>Remarks: No toxicity at the limit of solubility                        |
| Toxicity to algae/aquatic plants                                       | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility |
|  |   | NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 201<br>Remarks: No toxicity at the limit of solubility   |
| Toxicity to microorganisms   | : | EC50 : > 4.4 mg/l<br>Exposure time: 3 h<br>Test Type: Respiration inhibition<br>Method: OECD Test Guideline 209<br>Remarks: No toxicity at the limit of solubility              |
|  |   | NOEC : 4.4 mg/l<br>Exposure time: 3 h<br>Test Type: Respiration inhibition<br>Method: OECD Test Guideline 209<br>Remarks: No toxicity at the limit of solubility                |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

Toxicity to fish (Chronic toxicity) : NOEC: 0.051 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

NOEC: 4 mg/l  
Exposure time: 7 d  
Species: Cyprinodon variegatus (sheepshead minnow)  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.282 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

### 12.2 Persistence and degradability

#### Components:

##### **Atorvastatin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 7.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

##### **Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111

### 12.3 Bioaccumulative potential

#### Components:

##### **Atorvastatin:**

Partition coefficient: n-octanol/water : log Pow: 1.62

##### **Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Exposure time: 97 d  
Bioconcentration factor (BCF): 173  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

### 12.4 Mobility in soil

#### Components:

##### **Atorvastatin:**

Distribution among environmental compartments : log Koc: 2.84

##### **Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : UN 3077

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

**ADR** : UN 3077  
**RID** : UN 3077  
**IMDG** : UN 3077  
**IATA** : UN 3077

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)  
**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)  
**RID** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)  
**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Atorvastatin)  
**IATA** : Environmentally hazardous substance, solid, n.o.s.  
(Ezetimibe, Atorvastatin)

### 14.3 Transport hazard class(es)

|             | Class | Subsidiary risks |
|-------------|-------|------------------|
| <b>ADN</b>  | : 9   |                  |
| <b>ADR</b>  | : 9   |                  |
| <b>RID</b>  | : 9   |                  |
| <b>IMDG</b> | : 9   |                  |
| <b>IATA</b> | : 9   |                  |

### 14.4 Packing group

**ADN**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M7

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

Hazard Identification Number : 90  
Labels : 9

### IMDG

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

### 14.5 Environmental hazards

#### ADN

Environmentally hazardous : yes

#### ADR

Environmentally hazardous : yes

#### RID

Environmentally hazardous : yes

#### IMDG

Marine pollutant : yes

#### IATA (Passenger)

Environmentally hazardous : yes

#### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 3.2      Revision Date: 06.04.2024      SDS Number: 26489-00023      Date of last issue: 29.09.2023  
Date of first issue: 29.10.2014

the market and use of certain dangerous substances,  
mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

|    |                       | Quantity 1 | Quantity 2 |
|----|-----------------------|------------|------------|
| E2 | ENVIRONMENTAL HAZARDS | 200 t      | 500 t      |

### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

H410 : Very toxic to aquatic life with long lasting effects.

H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

|                   |      |
|-------------------|------|
| STOT RE 2         | H373 |
| Aquatic Chronic 2 | H411 |

### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ezetimibe / Atorvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 29.09.2023  |
| 3.2     | 06.04.2024     | 26489-00023 | Date of first issue: 29.10.2014 |

---

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN